Expert Interview
Examining Arcutis Bio’s Lead Pipeline Drug, ARQ-154 (Foam Roflumilast), as a Potential Treatment for Scalp and Body Psoriasis
Ticker(s): ARQTInstitution: Private Practice (Florida)
- Dermatologist at Riverchase Dermatology & volunteer clinical associate professor at the University of Miami School of Medicine.
- PI for several psoriasis trials; treats patients with scalp and body psoriasis and GPP.
- Involved in clinical research with a specialty interest in psoriasis, vitiligo, and complex medical dermatology.
Please tell us about your experience as a physician. How many patients with psoriasis, and do you treat? What % of patients need treatment for scalp and body psoriasis? Can you tell us some ways in which the field is advancing?
Added By: slingshot_insightsWhat is the first-line of treatment that you’re currently using? How has your approach changed in recent years?
Added By: slingshot_insightsWhat is the underlying mechanism of PDE4 inhibitor roflumilast, that decreases production of anti-inflammatory mediators? Currently, roflumilast is only approved in severe COPD, has its safety and efficacy profile been satisfactory in COPD patients so far?
Added By: slingshot_insightsWhat other targets are established in dermatology, besides PDE4 inhibition?
At week 8, roflumilast foam 0.3% achieved a S-IGA rate of 59.1% compared to a vehicle rate of 11.4%, and a B-IGA rate of 40.3% vs vehicle rate 6.8%. What would you attribute that difference in outcomes to?
Added By: slingshot_insights71% of subjects achieved an itch reduction of at least 4 points at week 8 compared to 18.5% of vehicle treated subjects. How important can this be for your patients? How does it compare to what you’ve been prescribing so far?
Added By: slingshot_insightsWhat is roflumilast foam’s potential, not just in psoriasis, but in treating seborrheic dermatitis as well?
How likely would you be to prescribe roflumilast to psoriasis patients, judging from the data available so far?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
